IPCA Laboratories Limited has informed the Exchange about Appointment of Dr. Nagaji Ambabhai Vekariya as President CRD
IPCALAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ipca Laboratories has appointed Dr. Nagaji Ambabhai Vekariya as President – Corporate Research & Development (CRD), effective June 16, 2025. He holds a PhD in Organic Chemistry from Saurashtra University and brings over 23 years of pharma industry experience. His prior stints include Alembic Pharmaceuticals, Glenmark, Lupin, Aurobindo, Macleods, Neuland Laboratories, and most recently Sekhmet Pharmaventures as Head of API & Formulations R&D. He is not related to any Director or Key Managerial Personnel of the company. The appointment has been disclosed to the exchanges under SEBI Listing Regulations.
A senior R&D hire with deep experience across leading Indian pharma companies signals Ipca's continued focus on strengthening its research pipeline and global regulatory capabilities, which is positive for long-term growth but unlikely to cause an immediate stock reaction.